JP2012523418A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523418A5
JP2012523418A5 JP2012504788A JP2012504788A JP2012523418A5 JP 2012523418 A5 JP2012523418 A5 JP 2012523418A5 JP 2012504788 A JP2012504788 A JP 2012504788A JP 2012504788 A JP2012504788 A JP 2012504788A JP 2012523418 A5 JP2012523418 A5 JP 2012523418A5
Authority
JP
Japan
Prior art keywords
alkyl
arylalkyl
cycloalkyl
heteroarylalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030130 external-priority patent/WO2010118055A1/en
Publication of JP2012523418A publication Critical patent/JP2012523418A/ja
Publication of JP2012523418A5 publication Critical patent/JP2012523418A5/ja
Pending legal-status Critical Current

Links

JP2012504788A 2009-04-09 2010-04-06 認知機能低下の阻害剤 Pending JP2012523418A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16798409P 2009-04-09 2009-04-09
US61/167,984 2009-04-09
US30866710P 2010-02-26 2010-02-26
US61/308,667 2010-02-26
US30909110P 2010-03-01 2010-03-01
US61/309,091 2010-03-01
PCT/US2010/030130 WO2010118055A1 (en) 2009-04-09 2010-04-06 Inhibitors of cognitive decline

Publications (2)

Publication Number Publication Date
JP2012523418A JP2012523418A (ja) 2012-10-04
JP2012523418A5 true JP2012523418A5 (enExample) 2013-05-23

Family

ID=42936539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504788A Pending JP2012523418A (ja) 2009-04-09 2010-04-06 認知機能低下の阻害剤

Country Status (12)

Country Link
US (3) US8765816B2 (enExample)
EP (1) EP2416795B1 (enExample)
JP (1) JP2012523418A (enExample)
CN (2) CN105968022A (enExample)
AU (2) AU2010234518A1 (enExample)
BR (1) BRPI1007624A2 (enExample)
DK (1) DK2416795T3 (enExample)
ES (1) ES2545795T3 (enExample)
IL (1) IL215645A0 (enExample)
RU (1) RU2595720C2 (enExample)
SG (2) SG176772A1 (enExample)
WO (1) WO2010118055A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118055A1 (en) 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
KR20140135835A (ko) 2012-03-20 2014-11-26 아다메드 에스피. 제트 오.오. Cns 질환의 치료를 위한 벤질아민의 설폰아미드 유도체
ES2769780T3 (es) 2013-10-28 2020-06-29 Univ Drexel Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease
WO2026136732A1 (en) 2024-12-18 2026-06-25 Cognition Therapeutics, Inc. Compositions and methods for the treatment of dementia with lewy bodies

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321386A (en) * 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
JPS62283922A (ja) * 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
JPH01180822A (ja) * 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
AU702629B2 (en) * 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
CN1093079A (zh) * 1993-03-30 1994-10-05 陈英俊 由具有愈创木酚结构之香辛类化合物及其去氢化合物衍生之肾上腺素激性乙型阻断剂
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
EP1207882A4 (en) * 1999-07-30 2003-03-19 Vertex Pharma DERIVATIVES OF ACYCLIC AND CYCLIC AMINES
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
WO2003016274A2 (en) * 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
JP2004002517A (ja) * 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
EP1635805A4 (en) 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 a-베타 올리고머의 정제 방법,당해 비확산성 a-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
EP1896005A4 (en) 2005-06-15 2009-11-11 Darrick S H L Kim SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
CA2644093A1 (en) 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. Extracts and methods comprising curcuma species
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
US7723377B2 (en) * 2006-09-29 2010-05-25 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
US7968524B2 (en) 2007-05-15 2011-06-28 Helicon Therapeutics, Inc. Methods of enhancing long term memory formation by inhibition of Gpr12
SI2206707T1 (sl) * 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
WO2010118055A1 (en) 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2013029057A2 (en) 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease

Similar Documents

Publication Publication Date Title
RU2011145321A (ru) Ингибиторы снижения когнитивных способностей
JPWO2022138987A5 (enExample)
JP2013501006A5 (enExample)
AU2010297557C1 (en) Lysine specific demethylase-1 inhibitors and their use
RU2003130268A (ru) Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
JP7026787B2 (ja) ヒストン脱アセチル化酵素1および/または2(hdac1-2)の選択的阻害剤としての新規なヘテロアリールアミド誘導体
CA2457444A1 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
JP2021105002A5 (enExample)
JP2013056919A5 (enExample)
RU2004107131A (ru) Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1- антагонистическую активность
RU2005103244A (ru) Производные 1h-1,2,4-триазол-3-карбоксамида в качестве лигандов рецептора каннабиноидов (cb1)
CA2462692A1 (en) Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
US9682950B2 (en) Thiophene-2-carboximidamide based selective neuronal nitric oxide synthase inhibitors
JP2023518776A (ja) シクロスポリン誘導体の調製
WO1996018608A1 (en) Aniline derivatives having nitrogen monoxide synthase inhibitory activity
JP2015516968A5 (enExample)
JP2017519796A5 (enExample)
RU2012107457A (ru) Ингибиторы ухудшения когнитивных способностей
AU2017202849C1 (en) Potent and Selective Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof
WO2023014793A1 (en) Process for polyamide synthesis
WO2013120045A1 (en) Substituted 1h-indazol-1-ol analogs as inhibitors of beta catenin/tcf protein-protein interactions
JP2018507230A5 (enExample)
CA2671482A1 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
RU2013158817A (ru) Способ синтеза и кристаллическая форма гидрохлорида 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1н)-ил]пропокси}бензамида и содержащие ее фармацевтические композиции